CytoDyn Inc. appointed Scott Kelly as board chairman.
Kelly, who has served as a member of the company's board since April 2017, succeeds Anthony Caracciolo, who will continue as a director.
Vancouver, Wash.-based CytoDyn develops humanized monoclonal antibodies to treat and prevent HIV infection.